Ebatid IV infusion
Dexa Medica
Ingredients in every 100 ml
Eptifibatide | 75 mg |
Each package contains
Other details
Flavour | None |
W.H.O. classification
ATC Level 1 | B - Blood and blood forming organs |
ATC Level 2 | B01 - Antithrombotic Agents |
ATC Level 3 | B01A - Antithrombotic Agents |
Warnings
Pregnancy
Lactation
Alcohol
Machinery
Available in
![]() |
Indonesia |
Dosage information
18 YEARS OLD AND ABOVE
Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction) with creatinin clearance ≥ 50 ml/minute: intravenous bolus 180 µg/kg, followed by continuous infusion 2.0 µg/kg/minute until hospital discharge or initiation of coronary artery bypass graft, up to 72 hours.
Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction) with creatinin clearance ≥30 – <50 ml/minute: intravenous bolus 180 µg/kg, followed by continuous infusion 1.0 µg/kg/minute until hospital discharge or initiation of coronary artery bypass graft, up to 72 hours.
Patients undergoing Percutaneous Coronary Intervention (PCI) with creatinin clearance ≥ 50 ml/minute: intravenous bolus 180 µg/kg before PCI, followed by continuous infusion 2.0 µg/kg/minute and a second 180 µg/kg bolus, 10 minutes after the first bolus injection.
Infusion should be continued until hospital discharge or maximum of 18-24 hours post-PCI, whichever comes first. A minimum of 12 hours of infusion is recommended.
Patients undergoing Percutaneous Coronary Intervention (PCI) with creatinin clearance ≥30 – <50 ml/minute: intravenous bolus 180 µg/kg before PCI, followed by continuous infusion 1.0 µg/kg/minute and a second 180 µg/kg bolus, 10 minutes after the first bolus injection.
Infusion should be continued until hospital discharge or maximum of 18-24 hours post-PCI, whichever comes first. A minimum of 12 hours of infusion is recommended.
0 TO 18 YEARS OLD
Safety and effectiveness have not been studied.
PATIENTS WITH ACUTE CORONARY SYNDROME
– Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction) with creatinin clearance ≥ 50 ml/minute:
patients weighing more than 121 kg should receive a maximum bolus of 22.6 mg followed by a maximum infusion rate of 15 mg per hour
– Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction) with creatinin clearance ≥30 – <50 ml/minute:
patients weighing more than 121 kg should receive a maximum bolus of 22.6 mg followed by a maximum infusion rate of 7.5 mg per hour
PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
– PCI with creatinin clearance ≥ 50 ml/minute:
patients weighing more than 121 kg should receive a maximum of 22.6 mg per bolus followed by a maximum infusion rate of 15 mg per hour.
– with creatinin clearance ≥30 – <50 ml/minute:
patients weighing more than 121 kg should receive a maximum of 22.6 mg per bolus followed by a maximum infusion rate of 7.5 mg per hour.
CORONARY ARTERY BYPASS GRAFT SURGERY
In patients who undergo coronary artery bypass graft surgery, eptifibatide infusion should be discontinued prior to surgery.
Indication
– For the treatment of patients with acute coronary syndrome (Unstable Angina (UA)/Non-Q Wave Myocardial Infarction (NQMI)), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, eptifibatide has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction.
– For the treatment of patients undergoing PCI, including those undergoing intracoronary stenting. In this setting, eptifibatide has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction, or need for urgent intervention.